Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

MIAMI, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, oncology, and viral induced acute respiratory distress syndrome, today announced it will host an investor conference call and audio webcast on Thursday, January 4, 2024, at 8:00 a.m. ET to discuss the recent financing and the Company’s strategy to prioritize the development of enobosarm for weight loss as well as provide an update on the Company’s drug pipeline.

“Veru is a late clinical stage biopharmaceutical company focusing on developing novel medicines for the treatment of obesity and oncology. We have made a major change on the clinical development of enobosarm, our novel small molecule, first-in-class oral selective androgen receptor modulator. Enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function in 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting. Because of these clinical attributes, enobosarm is being developed as an obesity treatment to augment fat loss while preventing muscle loss initially in sarcopenic obese or overweight elderly patients receiving a glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug for weight loss who are at-risk for developing muscle atrophy and muscle weakness,” said Mitchell S. Steiner, MD, Chairman, CEO and President of Veru Inc. “We plan to conduct a Phase 2b multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial designed to evaluate enobosarm 3mg, 6mg, or placebo in approximately 75 sarcopenic obese or overweight elderly patients receiving a GLP-1 RA for weight loss, with the first clinical data expected from the clinical trial in Q4 2024. Our recent financing should provide us with sufficient resources to reach beyond the clinical milestones associated with the Phase 2b enobosarm for obesity clinical trial.”

The audio webcast will be accessible under “Investor Kit” in the Investors page of the Company’s website at www.verupharma.com. To join the conference call via telephone, please dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international) and ask to join the Veru Inc. call. An archived version of the audio webcast will be available for replay on the Company’s website for approximately three months. A telephonic replay will be available on January 4, 2024 at approximately 12:00 p.m. ET by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international), passcode 7752713, for one week.